Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

Table 1 Summary of case reports of crizotinib (250 mg/b.i.d. orally) in treating MET-rearranged non-small cell carcinoma

Ref.	Age	Sex	Smoker	Stage	Histology	MET fusion	Best overall response	PFS (mo)	Grade ≥ 3 AEs	Notes
[5]	33	F	Yes	IV	ADC	KIF5B-MET	PR	8	NR
[5]	62	F	No	IV	ADC	STARD3NL-MET	PR	14	NR
[6]	51	F	No	IV	ADC	KIF5B-MET	PR	10	NR
[7]	74	F	No	Recurrent	ADC	HLA-DRB1-MET	Complete resolution of nodules while pleural effusion persisted	8	No
[8]	59	F	No	Recurrent	ADC	HLA-DRB1-MET	Complete radiographic response	/	No
[9]	43	F	No	IV	ADC	MET-UBE2H	PR	6.5	NR	MET fusion was acquired on EGFR-targeted therapy
[10]	56	F	No	IV	ADC	MET–ATXN7L1	PR	4	NR

ADC: Adenocarcinoma; AE: Adverse event; NR: Not reported; PR: Partial response.